Related Experiment Videos
Association of persistent bronchial hyperresponsiveness with beta2-adrenoceptor (ADRB2) haplotypes. A population
M D'amato1, L R Vitiani, G Petrelli
1Department of Immunobiology, Institute of Cell Biology-CNR; Laboratorio Epidemiologia e Biostatistica, Istituto Superiore di Sanità, Rome, Italy.
American Journal of Respiratory and Critical Care Medicine
|December 16, 1998
Summary
Genetic variations in the beta2-adrenoceptor gene (ADRB2) may predispose individuals to bronchial hyperresponsiveness (BHR). A specific ADRB2 haplotype is linked to BHR, suggesting a role in genetic susceptibility.
Area of Science:
- Genetics
- Pulmonology
- Pharmacogenomics
Background:
- Bronchial hyperresponsiveness (BHR) is a key characteristic of asthma and a significant risk factor.
- BHR is not exclusive to asthmatics and can occur in healthy individuals, potentially due to genetic factors.
- The beta2-adrenoceptor gene (ADRB2) and its polymorphisms at amino acid positions 16 and 27 are implicated in asthma clinical features, including airway reactivity.
Purpose of the Study:
- To investigate the influence of ADRB2 gene polymorphisms on bronchial hyperresponsiveness (BHR).
- To examine the association between specific ADRB2 haplotypes and BHR in a homogeneous population sample.
Main Methods:
- Studied a large, homogeneous sample for race, gender, age, and environment.
- Defined BHR by consistent positive responses to serial methacholine challenge tests.
- Analyzed genetic variability at the ADRB2 locus by identifying haplotypic combinations of polymorphisms at positions 16 and 27.
Main Results:
- Identified an association between the ADRB2 haplotype (Gly at position 16, Gln at position 27) and BHR.
- This association remained significant after adjusting for confounding variables like specific and total IgE levels.
Conclusions:
- The ADRB2 gene, specifically certain haplotypes, may confer genetic susceptibility to bronchial hyperresponsiveness (BHR).
- This suggests a role for ADRB2 in the genetic predisposition to BHR, beyond a mere disease-modifying effect in asthma.